Advisory Board
Corporate Advisory Board
VedTechBio’s Corporate Advisory Board brings together seasoned leader with deep expertise in Biomedical Research, Clinical Development, and Strategic Innovation. The collective experience guides the development of transformative healthcare technologies and supports VedTechBio’s mission to deliver impactful therapeutic solutions.
- Strategic Advisor, Corporate Advisory Board
- Chairman & CEO, Invea Therapeutics
- President & CEO, AlphaMeld Corporation
Dr. Krishnan Nandabalan is a visionary leader and serial biotech entrepreneur with over two decades of experience in the Pharmaceutical and Biotechnology Industries. His expertise spans Research and Development, Operations, Business Development, Mergers and Acquisitions, and Licensing Strategies.
Currently serving as Chairman & CEO of Invea Therapeutics and President & CEO of AlphaMeld Corporation, Dr. Nandabalan has been instrumental in pioneering the application of Artificial Intelligence (AI) and Machine Learning (ML) to accelerate drug discovery and healthcare innovation. He co-founded BioXcel Therapeutics (NASDAQ: BTAI), playing a pivotal role in its successful spinout.
Throughout his career, Dr. Nandabalan has forged strategic partnerships with global pharmaceutical leaders including AstraZeneca, Biogen, BMS, GSK, Pfizer, Novartis, and Takeda. His strategic vision and scientific acumen have consistently driven innovation at the intersection of Data Science and Medicine.
He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India, and completed his post-doctoral fellowship at Yale University. With 12 issued patents and publications in top-tier journals such as Cell and Science, Dr. Nandabalan brings a rare blend of scientific depth and strategic foresight to VedTechBio’s Advisory Board.